Phaseline

Targets › FLT4

FLT4 (Vascular endothelial growth factor receptor 3): drug programs, companies and trials

24 programs from 22 companies in 354 trials: 264 Phase 2, 44 Phase 1, 37 Phase 3, 9 Phase 4; Oncology, Other, Respiratory; next expected readout Dec 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. (UniProt, P35916)

Open in Phaseline: the race on FLT4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupCatequentinib
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 4Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma …Dec 2026
TakedaFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 4Colorectal CancerOct 2027
Shanghai Junshi Bioscience Co., Ltd.Lenvatinib mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Hepatocellular Carcinoma (HCC); Intrahepatic CholangiocarcinomaDec 2026
Ocular TherapeutixAxitinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) …Jan 2027
Chia Tai Tianqing Pharmaceutical GroupAL2846 Capsule
Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET
MET, KIT, FLT4, RETPhase 3Thyroid CancerJan 2027
University Hospital, BordeauxPD-1/PD-L1 ICI + VEGFR-TKI combination
PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor
PDCD1, CD274, KDR, FLT1, FLT4Phase 3Metastatic Renal Cell CarcinomaJan 2027
Merck & Co. (MSD)Lenvatinib (MK-7902)
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma …Feb 2027
Advenchen LaboratoriesCatequentinib (AL3818)
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 3Alveolar Soft Part SarcomaDec 2027
AO GENERIUMGNR-139
Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2
FLT1, KDR, FLT4Phase 3nAMDMay 2028
Hutchmedfruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 3Advanced Endometrial Cancer; Advanced Renal Cell CarcinomaJan 2029
Alliance for Clinical Trials in OncologyTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 3Clear Cell Renal Cell CarcinomaNov 2037
Avalyn PharmaNintedanib (AP02)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer …Dec 2026
Henan Cancer HospitalLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2EffectivenessDec 2026
Chipscreen BiosciencesIbcasertib
Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor
AURKB, FLT1, FLT4, KDRPhase 2Pancreatic Ductal AdenocarcinomaFeb 2027
City of Hope Medical CenterLenvatinib Mesylate
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Apr 2027
Tianjin Medical University Cancer Institute and HospitalAnlotinib Hydrochloride
multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor)
KDR, PDGFRA, FLT4Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerJun 2027
MannkindNintedanib (MNKD-201)
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 2Idiopathic Pulmonary FibrosisDec 2027
CriteriumFruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma …Dec 2027
HutchmedSurufatinib
Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor
FGFR1, FLT1, FLT4, KDRPhase 2Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma …May 2028
M.D. Anderson Cancer CenterTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 2Renal Cell CarcinomaNov 2028
University of FloridaTivozanib
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1Bile Duct CancerDec 2026
AstraZenecacediranib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
KIT, PDGFRB, PDGFRA, FLT1, FLT4Phase 1Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer …Dec 2026
Betta PharmaceuticalsX-82
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor
PDGFRB, PDGFRA, FLT1, FLT4, KDRPhase 1DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib …Jan 2027
National Cancer Institute (NCI)Tivozanib (AV-951)
Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor
FLT1, FLT4, KDR, KIT, PDGFRBPhase 1CholangiocarcinomaDec 2028

Conditions

Hepatocellular Carcinoma (13) Colorectal Cancer (12) Hepatocellular Carcinoma Non-resectable (7) Renal Cell Carcinoma (6) Intrahepatic Cholangiocarcinoma (6) Gastric Cancer (6) Breast Cancer (6) Metastatic Renal Cell Carcinoma (6) HCC (5) Cervical Cancer (5) Clear Cell Renal Cell Carcinoma (5) Hepatocellular Carcinoma (HCC) (5)

Modalities

small molecule (13), mixed (10), antibody (1)

Companies

Chia Tai Tianqing Pharmaceutical Group (2) Hutchmed (2) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Takeda (1) Tianjin Medical University Cancer Institute and Hospital (1) AO GENERIUM (1) Chipscreen Biosciences (1) National Cancer Institute (NCI) (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Advenchen Laboratories (1) Ocular Therapeutix (1) AstraZeneca (1) City of Hope Medical Center (1) Henan Cancer Hospital (1) Betta Pharmaceuticals (1)

Related targets

KDR (22) FLT1 (20) PDGFRB (10) KIT (8) PDGFRA (5) PDCD1 (1) CD274 (1) AURKB (1) MET (1) RET (1) FGFR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.